TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT)
On February 6, 2026, TD Cowen upgraded Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s price target to $21 from $20 while keeping a Buy rating, citing a Q4 beat and an improved outlook.






